Background {#Sec1}
==========

The estimated global prevalence of atrial fibrillation (AF) patients was 33.5 million patients in 2010 \[[@CR1]\]. Furthermore, approximately one-fourth of middle aged adults are expected to develop AF \[[@CR2], [@CR3]\], with an annual incidence rate of 120,000 to 215,000 patients in the European Union alone \[[@CR4]\]. AF patients are at two-fold increased risk of mortality \[[@CR5]\], in large part due to the elevated risk for cardiovascular disease (CVD). For example, it has been estimated that 20--30% of ischemic stroke patients have AF \[[@CR6]\]. While many advances in AF management such as anticoagulation therapy has been made \[[@CR7]\], substantial morbidity still remains \[[@CR8]\]. Therefore, identifying and managing modifiable risk factors for CVD among AF patients are of importance from clinical and public health perspectives.

Smoking is one of the most common health behavior factors related to CVD, and the effect of smoking on CVD among AF patients has previously been studied \[[@CR9], [@CR10]\]. Multiple longitudinal studies from developed countries such as the United Kingdom and Netherlands have shown that there was a higher risk for CVD among smokers compared to never smokers \[[@CR9], [@CR10]\]. However, such studies only determined smoking status at one point in time and thus could not elucidate whether the change in smoking habit over time alters the risk of CVD among AF patients \[[@CR9], [@CR10]\]. Moreover, there is a relative lack of evidence among populations residing in Asian countries. While recent AF management guidelines suggest behavioral modification including smoking cessation \[[@CR11]\], there is currently a lack of evidence on whether quitting after AF diagnosis actually leads to reduced CVD risk among smokers.

Therefore, in this longitudinal study using the Korean National Health Insurance Service (NHIS) database, we investigated the association of smoking habit change on the risk of CVD among newly diagnosed AF male patients.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

The study subjects were derived from the National Health Insurance Service -- Health Screening Cohort (NHIS-HEALS, NHIS-2018-2-118). In South Korea, the NHIS provides mandatory health insurance covering nearly all forms of health services for all Korean citizens, resulting in an enrollment rate of approximately 98% \[[@CR12]\]. Furthermore, all enrollees aged 40 years or older are required to undergo biannual health screening examinations that include a self-reported questionnaire on health behavior, body measurements including height, weight, and blood pressure, as well as blood and urine laboratory exams. Based on this claims database, the NHIS provides a part of their data for research purposes, which include information on sociodemographics, inpatient and outpatient hospital use, medication prescriptions, and results from health screening examinations \[[@CR13]\]. The NHIS database has previously been used for a wide range of epidemiological studies, and its validity is described in detail elsewhere \[[@CR12], [@CR14]\].

Study subjects and period {#Sec4}
-------------------------

Among 3562 newly diagnosed AF male patients (age 41--89 years) during 2003--2012, we excluded 909 patients who were diagnosed with CVD before the index date. Furthermore, 31 patients who died before the index date were also excluded. Finally, 212 and 38 patients with missing information on smoking status and covariates were excluded, respectively. The final study subjects consisted of 2372 AF patients (Fig. [1](#Fig1){ref-type="fig"}). Smoking status was determined within 2 years before and after AF diagnosis to determine smoking habit change. Starting from the index date of 2 years after AF diagnosis date, participants were followed-up until 2015 for CVD. Fig. 1Title Flow diagram of the study subjects

Key variables {#Sec5}
-------------

AF was defined as either a hospitalization or two or more outpatient department visits under the diagnosis of AF \[[@CR15]\]. Upon hospital use, the NHIS requires physicians to enter a diagnosis for all patients using the International Classification of Diseases, Tenth Revision (ICD-10) codes. The ICD-10 codes used for AF diagnosis were I48.0-I48.4, and I48.9 \[[@CR16]\] Similarly, CVD was defined upon two or more days of admission or death due to coronary heart disease (ICD-10 codes I20-I25) or total stroke (ICD-10 codes I60-I69) \[[@CR17]\]. Acute myocardial infarction (ICD-10 code I21) was also separately detected. Under total stroke, ischemic stroke (ICD-10 code I63) and hemorrhagic stroke (ICD-10 codes I61-I62) events were also determined.

Smoking status was determined by a self-reported questionnaire during health screening examinations within 2 years prior to (first health examination) and 2 years after (second health examination) AF diagnosis. The self-reported questionnaire requires the participant to choose between being a current smoker, past smoker, or never smoker according to his current smoking status at the time of the examination. Based on the smoking status from before and after AF diagnosis, all participants were grouped into either continual smokers, quitters, sustained ex-smokers, and never smokers. Continual smokers were those who were current smokers both before and after AF diagnosis. Quitters were participants who were current smokers before AF diagnosis that became quitters after AF diagnosis. Sustained ex-smokers were those who were quitters both before and after AF diagnosis. Finally, never smokers were participants who were never smokers both before and after AF diagnosis.

The considered covariates included age (continuous, years), household income (categorical, 1st, 2nd, 3rd, and 4th quartiles), alcohol consumption (categorical, 0, 0--1, 1--2, 3--4, and ≥ 5 times per week), physical exercise (categorical, 0, 1--2, 3--4, 5--6, and 7 times per week), body mass index (continuous, kg/m^2^), systolic blood pressure (continuous, mmHg), fasting serum glucose (continuous, mg/dL), total cholesterol (continuous, mg/dL), Charlson comorbidity index (categorical, ≤1, 2, 3, and ≥ 4), aspirin use (categorical, yes and no), warfarin use (categorical, yes and no), and index year. Household income was derived from the insurance premium and body mass index was calculated by dividing the height in meters by weight in kilograms squared. The algorithm for calculating Charlson comorbidity index from claims data was derived from a previous study \[[@CR18]\].

Statistical analysis {#Sec6}
--------------------

Multivariate Cox proportional hazards regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for CVD according to smoking habit change after adjustments for all covariates mentioned above. For all analyses, continual smokers were the reference group in order to assess the risk of quitting compared to continually smoking, which is in line with previous studies that also determined changes in smoking habit as the primary exposure \[[@CR14], [@CR19], [@CR20]\]. All participants were followed-up starting from the index until the date of CVD, death, or 31 December 2015, whichever came first. Furthermore, a stratified analysis for the association of smoking habit change on CVD according to subgroups of aspirin and warfarin use was conducted. Statistical significance was defined as a *p* value of \< 0.05 in a two sided manner. All data analyses were conducted using SAS version 9.4 (SAS Institute Inc).

Results {#Sec7}
=======

Table [1](#Tab1){ref-type="table"} depicts the descriptive characteristics of the study subjects. A total of 2372 AF patients were followed up for a mean (minimum-maximum) duration of 5.0 (0.1--10.8) years. The number of patients who were continual smokers, quitters, sustained ex-smokers, and never smokers were 475, 251, 779, and 867, respectively. The mean (standard deviation) age for continual smokers, quitters, sustained ex-smokers, and never smokers were 59.9 (9.4), 60.7 (9.6), 62.9 (9.9), and 64.1 (9.6) years, respectively. Compared to continual smokers, quitters tended to be older, have higher household income, consume less alcohol, have lower comorbidities, and use warfarin more. Table 1Basal characteristics of the study subjects according to groups of changes in smoking habitContinual smokersQuittersSustained ex-smokersNever smokersNumber of people475251779867Age, years, mean (SD)59.9 (9.4)60.7 (9.6)62.9 (9.9)64.1 (9.6)Household income, quartiles, N (%) 1st (highest)160 (33.7)101 (40.2)365 (46.9)377 (43.5) 2nd155 (32.6)65 (25.9)197 (25.3)238 (27.5) 3rd94 (19.8)55 (21.9)133 (17.1)145 (16.7) 4th (lowest)66 (13.9)30 (12.0)84 (10.8)107 (12.3)Alcohol consumption, times per week, N (%) 0146 (30.7)136 (54.2)356 (45.7)513 (59.2) 0--191 (19.2)42 (16.7)141 (18.1)143 (16.5) 1--2116 (24.4)43 (17.1)122 (15.7)116 (13.4) 3--460 (12.6)21 (8.4)95 (12.2)62 (26.1)  ≥ 562 (13.1)9 (3.6)65 (8.3)33 (3.8)Physical exercise, times per week, N (%) 0227 (47.8)133 (53.0)340 (43.7)407 (46.9) 1--2145 (30.5)53 (21.1)219 (28.1)206 (23.8) 3--456 (11.8)30 (12.0)121 (15.5)117 (13.5) 5--618 (3.8)13 (5.2)56 (7.2)54 (6.2) 729 (6.1)22 (8.8)43 (5.5)83 (9.6)Body mass index, kg/m^2^, mean (SD)23.8 (3.0)23.9 (3.1)24.4 (2.9)24.2 (2.8)Systolic blood pressure, mmHg, mean (SD)125.1 (16.5)124.5 (16.1)125.8 (15.7)126.6 (15.6)Fasting serum glucose, mg/dL, mean (SD)104.0 (32.3)103.1 (27.5)104.8 (28.2)102.8 (27.5)Total cholesterol, mg/dL, mean (SD)188.7 (36.1)192.2 (38.1)185.6 (35.2)182.3 (35.8)Charlson comorbidity index, N (%)  ≤ 1185 (39.0)84 (33.5)281 (36.1)333 (38.4) 2106 (22.3)49 (19.5)163 (20.9)172 (19.8) 380 (14.7)37 (14.7)128 (16.4)151 (17.4)  ≥ 4114 (24.0)81 (32.3)207 (26.6)211 (24.3)Aspirin use, N (%)277 (58.3)151 (60.2)501 (64.3)558 (64.4)Warfarin use, N (%)79 (16.6)58 (23.1)183 (23.5)232 (26.8)*Acronyms*: *SD* standard deviation

The association of smoking habit change on CVD among newly diagnosed AF male patients is shown in Table [2](#Tab2){ref-type="table"}. Compared to continual smokers, quitters had 35% reduced risk (aHR 0.65, 95% CI 0.44--0.97) and never smokers had 32% reduced risk (aHR 0.68, 95% CI 0.52--0.90) for CVD (*p* for trend 0.020). Similarly, quitters had 41% risk-reduction (aHR 0.59, 95% CI 0.35--0.99) and never smokers had 34% risk-reduction (aHR 0.66, 95% CI 0.46--0.93) for total stroke risk compared to continual smokers (*p* for trend 0.047). Finally, for ischemic stroke, quitters had 50% reduction (aHR 0.50, 95% CI 0.27--0.94), sustained ex-smokers had 36% reduction (aHR 0.64, 95% CI 0.42--0.99), and never smokers had 38% reduction (aHR 0.62, 95% CI 0.41--0.91) in risk compared to continual smokers (*p* for trend 0.047). There was a significant trend of risk reduction for CVD, total stroke, and ischemic stroke upon decreasing levels of tobacco consumption from continual smokers to never smokers. Table 2Hazard ratios for cardiovascular disease according to the change in smoking habit among atrial fibrillation male patientsContinual smokersQuittersSustained ex-smokersNever smokers*p* for trendCardiovascular disease Events9335110151 Person-years2407131233824666 aHR (95% CI)^a^1.00 (reference)0.65 (0.44--0.97)0.76 (0.57--1.02)0.68 (0.52--0.90)0.020Total stroke Events60206592 Person-years2541137435124871 aHR (95% CI)^a^1.00 (reference)0.59 (0.35--0.99)0.72 (0.50--1.04)0.66 (0.46--0.93)0.047Ischemic stroke Events46134464 Person-years2589139535684942 aHR (95% CI)^a^1.00 (reference)0.50 (0.27--0.94)0.64 (0.42--0.99)0.61 (0.41--0.91)0.047Hemorrhagic stroke Events63811 Person-years2687141436595117 aHR (95% CI)^a^1.00 (reference)0.96 (0.23--4.00)1.00 (0.34--3.00)0.88 (0.31--2.54)0.805Coronary heart disease Events44195379 Person-years2545134735274904 aHR (95% CI)^a^1.00 (reference)0.75 (0.43--1.29)0.77 (0.51--1.17)0.74 (0.50--1.10)0.189Acute myocardial infarction Events122420 Person-years2682141136745136 aHR (95% CI)^a^1.00 (reference)0.27 (0.06--1.23)0.21 (0.06--0.67)0.67 (0.31--1.45)0.530*Acronyms*: *aHR* adjusted hazard ratio, *CI* confidence interval^a^Hazard ratios calculated by Cox proportional hazards regression analysis after adjustments for age, household income, alcohol consumption, physical exercise, body mass index, systolic blood pressure, fasting serum glucose, total cholesterol, Charlson comorbidity index, aspirin use, warfarin use, and index year

Table [3](#Tab3){ref-type="table"} shows the stratified analysis for the association of smoking habit change on CVD according to subgroups of aspirin and warfarin use. Sustained ex-smokers had 45% reduced risk (aHR 0.55, 95% CI 0.34--0.90) and never smokers had 45% reduced risk (aHR 0.55, 95% CI 0.35--0.86) for CVD compared to continual smokers among aspirin non-users. Compared to continual smokers, sustained ex-smokers had 29% reduced risk (aHR 0.71, 95% CI 0.51--0.98) and never smokers had 27% reduced risk (aHR 0.73, 95% CI 0.54--0.99) for CVD among warfarin non-users. Never smokers among warfarin users had 48% reduced risk for CVD compared to continual smokers (aHR 0.52, 95% CI 0.28--0.97). Compared to continual smokers, sustained ex-smokers had 56% reduced risk for total stroke among aspirin non-users (aHR 0.44, 95% CI 0.21--0.91). Never smokers had 54% reduced risk for coronary heart disease among aspirin non-users (aHR 0.46, 95% CI 0.25--0.84, *p* for trend 0.018). Finally, never smokers had 59% reduced risk for coronary heart disease compared to continual smokers among warfarin users (aHR 0.41, 95% CI 0.20--0.86). Table 3Stratified analysis for the association of smoking habit change on cardiovascular disease according to subgroups of aspirin or warfarin useAdjusted hazard ratio (95% confidence interval)^a^Continual smokersQuittersSustained ex-smokersNever smokers*p* for trendCardiovascular diseaseAspirin use No1.00 (reference)0.59 (0.31--1.13)0.55 (0.34--0.90)0.55 (0.35--0.86)0.013 Yes1.00 (reference)0.70 (0.42--1.16)0.94 (0.65--1.35)0.80 (0.56--1.14)0.361Warfarin use No1.00 (reference)0.66 (0.43--1.03)0.71 (0.51--0.98)0.73 (0.54--0.99)0.073 Yes1.00 (reference)0.45 (0.18--1.13)0.85 (0.45--1.61)0.52 (0.28--0.97)0.088Total strokeAspirin use No1.00 (reference)0.63 (0.26--1.54)0.44 (0.21--0.91)0.71 (0.38--1.31)0.269 Yes1.00 (reference)0.83 (0.40--1.69)1.04 (0.61--1.77)0.79 (0.47--1.33)0.423Warfarin use No1.00 (reference)0.70 (0.38--1.29)0.74 (0.46--1.16)0.78 (0.51--1.20)0.343 Yes1.00 (reference)0.64 (0.17--2.46)0.85 (0.31--2.35)0.54 (0.20--1.49)0.255Coronary heart diseaseAspirin use No1.00 (reference)0.53 (0.22--1.29)0.60 (0.31--1.14)0.46 (0.25--0.84)0.018 Yes1.00 (reference)0.62 (0.32--1.19)0.87 (0.55--1.38)0.83 (0.54--1.29)0.661Warfarin use No1.00 (reference)0.64 (0.36--1.15)0.68 (0.44--1.04)0.74 (0.50--1.10)0.197 Yes1.00 (reference)0.32 (0.10--1.03)0.67 (0.32--1.42)0.41 (0.20--0.86)0.053^a^Hazard ratios calculated by Cox proportional hazards regression analysis after adjustments for age, household income, alcohol consumption, physical exercise, body mass index, systolic blood pressure, fasting serum glucose, total cholesterol, Charlson comorbidity index, aspirin use, warfarin use, and index year

Discussion {#Sec8}
==========

In this longitudinal study of 2372 newly diagnosed AF male patients, we have shown that smoking cessation after AF diagnosis was associated with reduced CVD, total stroke, and ischemic stroke risk. This association of CVD risk-reduction upon smoking cessation did not appear to alter significantly due to aspirin or warfarin use. To our knowledge, this is the first study to show that quitting after diagnosis of AF among smokers may benefit from reduced risk of CVD.

While we could not find any studies on the association of smoking habit change on CVD risk among AF patients, multiple previous studies have investigated the effect of smoking measured at one point in time on CVD risk among AF patients. In a study that investigated risk factors for stroke among AF patients, the risk of stroke was not elevated among current smokers compared to never smokers (*p* value 0.08) \[[@CR21]\]. However, another study by Lip and colleagues showed that smoking was associated with higher thromboembolic event risk (aHR 2.10, 95% CI 1.38--3.18) \[[@CR10]\]. Similarly, a recent study by Albertsen and colleagues have shown that smoking was associated with higher risk of thromboembolism \[[@CR9]\]. Current male smokers with ≤25 g/d (aHR 1.66, 95% CI 1.30--2.12) and \> 25 g/day (aHR 2.17, 95% CI 1.59--2.95) of tobacco consumption had elevated risk for thromboembolism compared to never smokers \[[@CR9]\]. Our study adds to the results from previous investigations by showing that smoking cessation was associated with reduced CVD risk among AF patients who initially smoked.

Multiple pathophysiological mechanisms may be at play in the risk-increasing effect of smoking on CVD. Smoking has been shown to reduce vasodilatory function in both human \[[@CR22]\] and animal \[[@CR23]\] models, partly by decreasing nitric oxide availability \[[@CR24]\]. Furthermore, smoking also may increase peripheral leukocyte count \[[@CR25]\], C-reactive protein levels \[[@CR26]\], and interleukin-6 \[[@CR27]\], all of which are associated with inflammation. Both vasomotor dysfunction and increases in systemic inflammatory states could lead to higher risk for atherosclerosis, which in turn could result in CVD \[[@CR28]\]. Additionally, smoking has previously been shown to elevate low-density lipoprotein and triglyceride levels, while reducing high-density lipoprotein (HDL) \[[@CR29]\]. This may be achieved in part by increasing lipid oxidation \[[@CR30]\] and inhibiting lecithin cholesterol acyl-transferase activity \[[@CR31]\], an important enzyme that helps maintain HDL levels \[[@CR32]\].

Another primary mechanism of smoking on increasing CVD risk is by promoting a hypercoagulable state by inducing platelet dysfunction \[[@CR33]\] and alteration of antithrombotic factors \[[@CR34]\]. Therefore, whether antithrombotic therapy such as aspirin and warfarin medication, which are frequently prescribed in AF patients, alters the risk-reducing effect of quitting on CVD is of clinical importance. We have thus conducted a stratified analysis on the association between smoking habit change and CVD according to subgroups of aspirin and warfarin use. Despite the lack of significance likely due to the reduction in statistical power, the risk of CVD, total stroke, and coronary heart disease upon smoking cessation did not appear to alter significantly according to aspirin or warfarin use. Consequently, the antithrombotic effect of aspirin and warfarin does not appear to attenuate the risk-reducing effect of quitting on CVD risk among AF patients.

Several limitations must be considered when interpreting the results from our study. First, as smoking status was determined using a self-reported questionnaire, there could have been an underestimation of current smokers. This may be particularly true for past smokers, which could partly explain the lack of significant CVD risk-reduction among sustained ex-smokers since this group may actually contain current smokers who reported having quit during the health screening. Therefore, future studies that use a more reliable method of smoking status, such as urine cotinine levels, are needed to validate the findings of this study. Second, we did not take into account additional changes in smoking habit beyond the index date, due to the low number of participants who underwent health examinations after the index date. Since many smokers are unable to maintain quitting beyond one year \[[@CR35]\], a number of patients grouped as quitters in our study may actually have become current smokers after the index date (i.e. relapsers), possibly leading to an underestimation of the risk-reducing effect of quitting on CVD. Moreover, participants who were never smokers may have initiated smoking after the index date. Future studies that take into account multiple smoking status changes are needed to validate our findings.

Third, the study subjects consisted of male patients who underwent health screening examinations, which may be associated with certain sociodemographic tendencies. Although we attempted to take this into account by adjusting for a number of sociodemographic and health behavior factors, future studies with study subjects that include women and a more general population are needed. Fourth, we could not take into account the severity of AF due to the lack of data on medical chart records, which could be an important confounder in our study. Although we attempted to take this into account by limiting the study subjects to newly diagnosed patients, future studies that use health records to determine AF severity would be beneficial. Finally, we could not accurately assess the association of smoking cessation after AF diagnosis on the risk of acute myocardial infarction due to the lack of enough cases (2 cases of acute myocardial infarction among quitters) despite the observed significant aHR value. Future studies with a greater number of study subjects and acute myocardial infarction cases are needed.

Despite these limitations, our study has a number of strengths. First, we determined smoking status before and after AF diagnosis, which enabled us to investigate the risk of CVD according to the change in smoking habit. Second, the study subjects consisted of AF patients, a group that has not previously been studied on the association between smoking habit change and CVD risk. Third, the extensive list of covariates spanning from sociodemographic factors to health behavior and health status allowed us to enhance the reliability of our findings. Finally, the longitudinal design gives support to the cause-and-effect relationship of smoking habit change having effects on CVD risk.

Conclusions {#Sec9}
===========

Quitting was associated with decreased CVD risk among newly diagnosed AF male patients in South Korea. The beneficial effect of smoking cessation on CVD risk did not appear to be altered significantly by aspirin or warfarin use. Future prospective, intervention studies are needed to determine whether smokers who quit after AF diagnosis may benefit from reduced CVD risk.
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